Galderma's Record 2024: A Growth Story for Investors

Galderma Group AG, the pure-play dermatology category leader, has announced its financial results for the full year 2024, delivering record net sales and profitability. The company achieved record net sales of 4,410 million USD, up 9.3% year-on-year on a constant currency basis, and a record Core EBITDA of 1,031 million USD. Galderma's strong performance in 2024 sets the stage for continued growth in 2025 and beyond.

Galderma's growth in 2024 was driven by broad-based performance across all product categories, with Injectable Aesthetics and Dermatological Skincare leading the way. The company's unique Integrated Dermatology Strategy, focusing on a broad portfolio, global scale, and market-leading education and services, has enabled Galderma to differentiate itself from competitors and drive long-term success.

Key factors contributing to Galderma's record 2024 include:

1. Broad-based growth across product categories: Galderma achieved strong performance across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Injectable Aesthetics and Dermatological Skincare grew by 9.6% and 10.7% respectively on a constant currency basis.
2. International markets' performance: Galderma's larger reporting geography, International, contributed significantly to its growth, with a 59% share of Group sales at the end of the nine-month period. International markets maintained double-digit growth momentum, fueled by strong performance across major markets like China, Europe, and Latin America.
3. Innovation and new product launches: Galderma's commitment to innovation and new product launches has driven growth. For example, the successful launch of Nemluvio® (nemolizumab) for adult patients with prurigo nodularis in the U.S. contributed to the company's growth.
4. Focused strategic execution: Galderma's growth-focused Integrated Dermatology Strategy has enabled the company to advance all its product categories and future growth drivers through key approvals and new product launches. This strategy, combined with high-performing commercial execution and increasing penetration in existing and new key markets, sets the stage for further growth acceleration and value creation.

Galderma's record 2024 demonstrates the company's ability to deliver consistent growth and stability, driven by its balanced portfolio of growth and value stocks, strategic acquisitions, and integrated dermatology strategy. As Galderma continues to execute on its growth-focused Integrated Dermatology Strategy, investors can expect the company to maintain its strong performance and accelerate its growth trajectory into 2025 and beyond.